Pain in PsA = predictor of disability and QoL TYK-2 inhibition lowered clinical pain outcomes and ALSO pain-associated biomarkers vs PBO @RheumNow #ACR24 Abstract #2366 https://t.co/DAgmdmmTE0

• https://x.com/Dr_Brian_MD/status/1857432793917030906/photo/1

🔍 Safety of a JAKi Across 15,000 Patient-Years of Data Now in the RheumNow poster hall: Safety outcomes with a JAKi from 11 Phase 3 trials in adult patients with RA, PsA, AS, and nr-axSpA. Sponsored by AbbVie US Medical Affairs. https://t.co/yeif38wKIY https://t.co/earZnqZLSI

• Safety of a JAKi Across 15,000 Patient-Years of Data | RheumNow

Summary of treatments in psoriatic arthritis #PsA @RheumNow #ACR24 https://t.co/EybzRCPLtA

• https://x.com/synovialjoints/status/1857419269358666103/photo/1